Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 11/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 4/20 | 0.41 |
| ▸ | SLC8A1 | P32418 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478899 | 0.78 | KCNK3 (0.61) | KCNK3KCNK9ALDH1A1LMNAPDE2A | |
| SCHEMBL13801055 | 0.74 | KCNK3 (1.00) | KCNK3KCNK9PDE2A | |
| SCHEMBL29761432 | 0.74 | KCNK3 (1.00) | KCNK3KCNK9PDE2A | |
| SCHEMBL27620171 | 0.74 | KCNK3 (0.66) | KCNK3KCNK9KDM4EALDH1A1LMNA | |
| SCHEMBL498597 | 0.74 | KCNK3 (1.00) | KCNK3KCNK9PDE2A | |
| SCHEMBL498598 | 0.74 | KCNK3 (1.00) | KCNK3KCNK9PDE2A | |
| SCHEMBL14306639 | 0.71 | KCNK3 (0.55) | KCNK3KCNK9PDE2ASLC8A1 | |
| SCHEMBL14498283 | 0.68 | KCNA5 (0.77) | KCNK3KCNK9ALDH1A1HPGDTSHR | |
| SCHEMBL15166013 | 0.67 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL15166095 | 0.67 | KCNK3 (1.00) | KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106099-B2 | 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide or other phenylcarboxamide derivatives with dofetilide, ibutilide, almokalant, sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine as IKr chahel blocker | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20090209767-A1 | 2-(Butyl-1-sulfonylamino)-n-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| EP-2012758-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | Sanofi-Aventis Deutschland GmbH (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-20080081926-A1 | SULFONYLAMINOBENZOIC ACID AND SALT | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20060142350-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20040192738-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038083-A1 | Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias | KCNH2, KCNJ2, KCNH1 | KCNK3 33/4885KCNK9 43/4885KDM4E 267/4885 |
| US-20060142350-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | SCN1A, KCNH1, SCN1B | KCNK3 84/4885KCNK9 119/4885KDM4E 2089/4885 |
| US-20050054673-A1 | Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias | SCN5A, KCNH1, KCNA5 | KCNK3 84/4885KCNK9 114/4885KDM4E 1889/4885 |
| US-20080081926-A1 | SULFONYLAMINOBENZOIC ACID AND SALT | SLC5A1, SLC5A2, SLC1A5 | KCNK3 842/4885KCNK9 774/4885KDM4E 1727/4885 |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | KCNK3 18/4885KCNK9 106/4885KDM4E 1415/4885 |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | KCNJ2, KCNH2, KCNK5 | KCNK3 31/4885KCNK9 45/4885KDM4E 217/4885 |
| US-20090209767-A1 | 2-(Butyl-1-sulfonylamino)-n-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound | KCNH1, KCNA1, SCN5A | KCNK3 80/4885KCNK9 99/4885KDM4E 1605/4885 |
| US-20040192738-A1 | 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl] benzamide, its use as a medicament, and pharmaceutical preparations comprising it | SCN1A, SCN1B, KCNH1 | KCNK3 111/4885KCNK9 142/4885KDM4E 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.